{"id":22512,"date":"2026-01-29T12:44:23","date_gmt":"2026-01-29T11:44:23","guid":{"rendered":"https:\/\/www.biolife-publisher.it\/ejnd\/?p=22512"},"modified":"2026-03-11T13:08:45","modified_gmt":"2026-03-11T12:08:45","slug":"role-of-toll-like-receptors-in-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/","title":{"rendered":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE"},"content":{"rendered":"

E. Mazzon1<\/sup>, T. Paolucci2<\/sup> and O. Trubiani3*<\/sup><\/p>\n

1 <\/sup>Department of Medical, Oral and Biotechnological Sciences, University \u201cG. D’Annunzio\u201d of Chieti-Pescara, Chieti, Italy;
\n2 <\/sup>Department of Medicine and Ageing Sciences, University \u201cG. D’Annunzio\u201d of Chieti\u2010Pescara, Chieti, Italy;
\n3<\/sup> Department of Innovative Technologies in Medicine & Dentistry, University \u201cG. D’Annunzio\u201d of Chieti\u2010Pescara, Chieti, Italy.<\/p>\n

*Correspondence to<\/em>:
\nOriana Trubiani,
\nDepartment of Innovative Technologies in Medicine & Dentistry,
\nUniversity “G. d’Annunzio” Chieti-Pescara,
\n66100 Chieti, Italy.
\ne-mail: trubiani@unich.it<\/p>\n\n\n\n
Received: 05 February, 2025
\nAccepted: 10 March, 2025\"adobe-pdf-download-icon\"<\/a><\/td>\n		ISSN 2279-5855 print
\nISSN 2974-6345 online. Copyright \u00a9 by BIOLIFE 2025
\nThis publication and\/or article is for individual use only and may not be further reproduced without written permission from the copyright holder. Unauthorized reproduction may result in financial and other penalties. Disclosure: All authors report no conflicts of interest relevant to this article.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ABSTRACT<\/strong><\/p>\n

Toll-like receptors (TLRs) are a group of pattern recognition receptors (PRRs) that play a key role in both infections and innate immunity. To date, 11 TLRs have been described that recognize pathogen-associated molecular patterns (PAMPs) expressed on infectious agents. In Alzheimer’s disease (AD), TLRs modulate cytokine-mediated inflammation and participate in the innate immune response by mediating neuroinflammation. TLRs modulate the immune system and participate in the clearance of amyloid-beta (A\u03b2) in AD. A\u03b2 molecules activate the immune system and TLRs can interact with NOD-like receptors (NLRs) to activate inflammasomes. IL-1 is generated by microglia in response to A\u03b2 plaques \u00a0and plays a crucial role in AD when it is overproduced by causing inflammation and fever. TLR activation in AD leads to the production of pro-inflammatory cytokines such as IL-1 that induce neuroinflammation and worsen AD.<\/p>\n

KEYWORDS:<\/strong> Alzheimer\u2019s Disease, neurodegeneration, Toll-like receptor, pattern recognition receptor, inflammation<\/em><\/p>\n

\u00a0<\/strong><\/p>\n

INTRODUCTION<\/strong><\/p>\n

 <\/p>\n

Toll-like receptor (TLR) family proteins are a group of pattern recognition receptors (PRRs), which play a fundamental role in pathogen recognition and activation of innate immunity (1).\u00a0 In the innate immune response, PRRs play a critical role system by recognizing pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (2). There are 11 TLRs, numbered TLR1 through TLR11 (Table I).<\/p>\n

 <\/p>\n

Table I.<\/strong> The biological effects of TLRs.<\/em><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
TLR1\/TLR2 (Heterodimer): <\/em><\/td>\nRecognizes lipoproteins and lipopeptides from bacteria, as well as some fungal components.<\/td>\n<\/tr>\n
TLR2: <\/em><\/td>\nDetects lipoteichoic acid from Gram-positive bacteria and lipopeptides.<\/td>\n<\/tr>\n
TLR3: <\/em><\/td>\nRecognizes double-stranded RNA (dsRNA) from viruses.<\/td>\n<\/tr>\n
TLR4: <\/em><\/td>\nRecognizes lipopolysaccharides (LPS) from Gram-negative bacteria.<\/td>\n<\/tr>\n
TLR5: <\/em><\/td>\nRecognizes bacterial flagellin.<\/td>\n<\/tr>\n
TLR6\/(TLR2) (Heterodimer):<\/em><\/td>\nDetects lipoteichoic acid from Gram-positive bacteria and lipopeptides.<\/td>\n<\/tr>\n
TLR7: <\/em><\/td>\nRecognizes single-stranded RNA (ssRNA), particularly from viruses.<\/td>\n<\/tr>\n
TLR8: <\/em><\/td>\nAlso recognizes ssRNA, similar to TLR7.<\/td>\n<\/tr>\n
TLR9: <\/em><\/td>\nRecognizes unmethylated CpG DNA motifs commonly found in bacterial and viral DNA.<\/td>\n<\/tr>\n
TLR10: <\/em><\/td>\nThe specific ligand is not fully understood, but it may have regulatory roles in the immune response.<\/td>\n<\/tr>\n
TLR11: <\/em><\/td>\nIn mice, plays a role in recognizing pathogens such as Toxoplasma gondii.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

TLRs are highly conserved from Drosophila<\/em> to humans and share structural and functional similarities. They recognize PAMPs that are expressed on infectious agents and mediate the production of cytokines necessary for the development of effective immunity (3). PRRs play a key role in the innate immune system by recognizing PAMPs and damage-associated molecular patterns (DAMPs).\u00a0 In Alzheimer’s disease (AD), TLRs have a dual role: They modulate cytokine-mediated inflammation, and they intervene in the immune response \u201cin toto<\/em>\u201d. TLRs participate in neuroinflammation in AD and TLR2, TLR4 and TLR9, are activated by amyloid-beta (A\u03b2) plaques (4).<\/p>\n

 <\/p>\n

DISCUSSION<\/strong><\/p>\n

 <\/p>\n

A\u03b2 functions as a DAMP, triggering TLR-mediated inflammatory pathways (5). TLRs are expressed by microglia cells that inhabit the brain and mediate their activation (6). A\u03b2 plaques are capable of activating microglia, causing a neuroinflammatory cascade with cytokine production.<\/p>\n

Microglia cells are similar to macrophages and when they come into contact with A\u03b2 plaques, they phagocytose them, releasing inflammatory compounds that exacerbate AD pathology (7).\u00a0 The production of cytokines through TLR activation leads to the activation of NF-\u03baB, which leads to the transcription and translation of inflammatory cytokines such as IL-1, TNF, IL-6, and IL-18. At the same time, chemokines are also generated and released which contributes to the neuroinflammation (8).<\/p>\n

It is possible that anti-inflammatory cytokines, such as IL-10, IL-37, and IL-38, are also released, but probably in insufficient amounts to inhibit inflammation in AD (9).\u00a0Therefore, cytokine dysregulation is one of the important features in this neurodegenerative disease. In AD, TLRs not only modulate the immune system, but also participate in A\u03b2 clearance. In fact, TLR4 promotes microglia phagocytosis to promote A\u03b2 clearance (10). The effect of TLR4 also improves astrocyte degradation (11). Regulating TLR could improve the immune system with positive effects on both A\u03b2 clearance and local and systemic inflammation. Activation of TLR9 has neuroprotective effects and can also have a positive effect on inflammation, as has been demonstrated in experimental models (12).<\/p>\n

TLRs are dysregulated in AD and do not permit the correct immune response. A\u03b2 molecules continuously activate the immune system to overreact. TLRs can interact with NOD-like receptors (NLRs) to activate inflammasomes, such as NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), exacerbating inflammation through caspase-1 activation and the release of cytokines such as IL-1\u03b2. It is known that some TLRs, such as TLR2, TLR4, and TLR9, specifically participate in the pathological effect that occurs in AD (13) (Fig.1).<\/p>\n

 <\/p>\n

\"\"<\/p>\n

Fig. 1.<\/strong> Toll-like receptors (TLRs)-2 and 4 start a cascade that leads to inflammation and immunoregulation in Alzheimer\u2019s disease (AD) (arrows mean activation).<\/em><\/p>\n

 <\/p>\n

TLR2 recognizes A\u03b2 oligomers, contributes to the production of pro-inflammatory cytokines, and is linked to cognitive decline in AD, while TLR4 promotes A\u03b2 clearance. TLR9 has been shown to be neuroprotective and interacts with mitochondrial DNA released from damaged neurons (14). These effects suggest a role for TLR9 in AD therapy. Recently, it has been seen that rat TLR1 (or CD281) polyclonal antibody (concentration: 0.25 mg\/ml purified IgG) work with the selective affinity and could be used to treat AD (15). Targeting and modulating TLR could be an important new therapeutic strategy, as currently AD drugs are limited and nonspecific (16). One of the interesting strategies would be to stimulate the neuroprotective TLR9 with the hope of increasing the clearance of A\u03b2 (17).\u00a0 The specific inhibition of TLR2 and 4 would reduce the production of pro-inflammatory cytokines improving the health status in AD (18). In addition, the therapeutic use of inhibitory cytokines such as IL-37 and IL-38 that significantly reduce IL-1b could be another therapeutic option (19).<\/p>\n

 <\/p>\n

IL-1 and Alzheimer\u2019s disease (AD)<\/em><\/p>\n

IL-1 is an important cytokine of the immune system that plays a crucial role in AD (20).\u00a0In addition to being an immune molecule, when it is overproduced, IL-1 causes inflammation and fever (21). It is produced in the brain mostly by microglia in response to A\u03b2 plaques.\u00a0 This cytokine can aggregate A\u03b2 plaques and cause hyperphosphorylation of tau<\/em> protein, worsening neuronal dysfunction and synaptic efficiency (22).<\/p>\n

Targeting IL-1 can improve neuroinflammation in AD. IL-1 and TLR have similar pathways and interact to increase the inflammatory response (23,24). In fact, TLR activation in microglia leads to increased signaling of MyD88, the precursor of IL-1, which in turn re-stimulates IL-1. This creates a vicious cycle where IL-1 induces IL-1 to create the chronic and self-sustaining inflammatory state observed in AD (25). NLRP3 is a multiprotein complex that is part of the innate immune system and acts as an intracellular sensor that detects a broad range of microorganisms (26). When activated, it leads to the cleavage of pro-caspase-1 into its active form, caspase-1, triggering an inflammatory response with the release of the pro-inflammatory cytokine IL-1 (27,28).<\/p>\n

Activation of NLRP3 in microglia plays a significant neuroinflammatory role in the pathogenesis of AD and potential therapies have now been shown to target the NLRP3 inflammasome (26). Microglial cells recognize A\u03b2 and activate the NLRP3 inflammasome, an effect which is also exerted by hyperphosphorylated tau<\/em> aggregates. In AD, excessive production of IL-1\u03b2 contributes to neuronal damage, and chronic activation of NLRP3 impairs phagocytosis of microglial cells (29).<\/p>\n

 <\/p>\n

CONCLUSIONS<\/strong><\/p>\n

 <\/p>\n

In conclusion, TLR activation in AD leads to the production of pro-inflammatory cytokines and results in neuroinflammation. Targeting TLRs with different specific strategies or inhibiting pro-inflammatory cytokines could be used for new therapies that are currently needed due to the lack of pharmacological tools. AD is increasing in the population, especially in the elderly, and continued research is vital for creating new therapies. In AD, TLRs play an important role in cytokine-mediated neuroinflammation and also in the clearance of A\u03b2. Targeting TLRs represents a promising therapeutic option in this severe debilitating disease.<\/p>\n

 <\/p>\n

Conflict of interest <\/em><\/p>\n

The authors declare that they have no conflict of interest.<\/p>\n

 <\/p>\n

REFERENCES<\/strong><\/p>\n

    \n
  1. McCarthy GM, Bridges CR, Blednov YA, Harris RA. CNS cell-type localization and LPS response of TLR signaling pathways. F1000Research<\/em>. 2017;6:1144. doi:https:\/\/doi.org\/10.12688\/f1000research.12036.1<\/li>\n
  2. Narayanankutty A, Sasidharan A, Job JT. Targeting Toll like Receptors in Cancer: Role of TLR Natural and Synthetic Modulators. Curr Pharm Des<\/em>. 2020;26(39):5040-5053. doi:10.2174\/1381612826666200720235058<\/li>\n
  3. Kumar V, Stewart IV JH. Pattern-Recognition Receptors and Immunometabolic Reprogramming: What We Know and What to Explore. Journal of Innate Immunity<\/em>. 2024;16(1):295-323. doi:https:\/\/doi.org\/10.1159\/000539278<\/li>\n
  4. Zolezzi JM, Inestrosa NC. Wnt\/TLR Dialog in Neuroinflammation, Relevance in Alzheimer\u2019s Disease. Frontiers in Immunology<\/em>. 2017;8. doi:https:\/\/doi.org\/10.3389\/fimmu.2017.00187<\/li>\n
  5. Abulfadl Y, El-Maraghy N, Ahmed AE, Nofal S, Abdel-Mottaleb Y, Badary O. Thymoquinone alleviates the experimentally induced Alzheimer\u2019s disease inflammation by modulation of TLRs signaling. Human & Experimental Toxicology<\/em>. 2018;37(10):1092-1104. doi:https:\/\/doi.org\/10.1177\/0960327118755256<\/li>\n
  6. Kann O, Almouhanna F, Chausse B. Interferon \u03b3: a master cytokine in microglia-mediated neural network dysfunction and neurodegeneration. Trends in Neurosciences<\/em>. 2022;45(12):913-927. doi:https:\/\/doi.org\/10.1016\/j.tins.2022.10.007<\/li>\n
  7. Boza-Serrano A, Ruiz R, Sanchez-Varo R, et al. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer\u2019s disease. Acta Neuropathologica<\/em>. 2019;138(2):251-273. doi:https:\/\/doi.org\/10.1007\/s00401-019-02013-z<\/li>\n
  8. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature<\/em>. 2017;541(7638):481-487. doi:https:\/\/doi.org\/10.1038\/nature21029<\/li>\n
  9. Yang R, Duan J, Luo F, Tao P, Hu C. IL-6, IL-8 and IL-10 polymorphisms may impact predisposition of Alzheimer’s disease: a meta-analysis. Acta Neurol Belg<\/em>. 2021;121(6):1505-1512. doi:10.1007\/s13760-020-01369-4<\/li>\n
  10. Lee JW, Nam H, Kim LE, et al. TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia. Autophagy<\/em>. 2018;15(5):753-770. doi:https:\/\/doi.org\/10.1080\/15548627.2018.1556946<\/li>\n
  11. Li L, Acioglu C, Heary RF, Elkabes S. Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. Brain Behav Immun<\/em>. 2021;91:740-755. doi:10.1016\/j.bbi.2020.10.007<\/li>\n
  12. Packard AE, Leung PY, Vartanian KB, Stevens SL, Bahjat FR, Stenzel-Poore MP. TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning. J Cereb Blood Flow Metab<\/em>. 2012;32(12):2193-2200. doi:10.1038\/jcbfm.2012.140<\/li>\n
  13. Pourbadie HG, Sayyah M, Khoshkholgh-Sima B, et al. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer\u2019s disease\u2013related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. Neurobiology of Aging<\/em>. 2018;70:203-216. doi:https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.06.020<\/li>\n
  14. Ye L, Feng Z, Doycheva D, et al. CpG-ODN exerts a neuroprotective effect via the TLR9\/pAMPK signaling pathway by activation of autophagy in a neonatal HIE rat model. Exp Neurol<\/em>. 2018;301(Pt A):70-80. doi:10.1016\/j.expneurol.2017.12.008<\/li>\n
  15. Liu L, Lan X, Li J, et al. [Preparation and identification of the polyclonal antibody against extracellular domain (405T-573Q) of rat Toll-like receptor 2]. PubMed<\/em>. 2015;31(1):114-118.<\/li>\n
  16. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduction and Targeted Therapy<\/em>. 2023;8(1). doi:https:\/\/doi.org\/10.1038\/s41392-022-01304-4<\/li>\n
  17. Ye L, Feng Z, Doycheva D, et al. CpG-ODN exerts a neuroprotective effect via the TLR9\/pAMPK signaling pathway by activation of autophagy in a neonatal HIE rat model. Experimental Neurology<\/em>. 2017;301:70-80. doi:https:\/\/doi.org\/10.1016\/j.expneurol.2017.12.008<\/li>\n
  18. Dallas M, Widera D. TLR2 and TLR4-mediated inflammation in Alzheimer\u2019s disease: self-defense or sabotage? Neural Regeneration Research<\/em>. 2021;16(8):1552. doi:https:\/\/doi.org\/10.4103\/1673-5374.303016<\/li>\n
  19. Lauritano D, Mastrangelo F, D\u2019Ovidio C, et al. Activation of Mast Cells by Neuropeptides: The Role of Pro-Inflammatory and Anti-Inflammatory Cytokines. International Journal of Molecular Sciences<\/em>. 2023;24(5):4811. doi:https:\/\/doi.org\/10.3390\/ijms24054811<\/li>\n
  20. Li C, Zhang X, Wang Y, Cheng L, Li C, Xiang Y. The role of IL-1 family of cytokines in the pathogenesis and therapy of Alzheimer\u2019s disease. Inflammopharmacology<\/em>. 2024;32(5):2681-2694. doi:https:\/\/doi.org\/10.1007\/s10787-024-01534-8<\/li>\n
  21. Spulber S, Schultzberg M. Connection between inflammatory processes and transmittor function\u2014Modulatory effects of interleukin-1. Progress in Neurobiology<\/em>. 2009;90(2):256-262. doi:https:\/\/doi.org\/10.1016\/j.pneurobio.2009.10.015<\/li>\n
  22. Zhang Y, Zhao Y, Zhang J, Yang G. Mechanisms of NLRP3 Inflammasome Activation: Its Role in the Treatment of Alzheimer\u2019s Disease. Neurochemical Research<\/em>. 2020;45(11):2560-2572. doi:https:\/\/doi.org\/10.1007\/s11064-020-03121-z<\/li>\n
  23. Loiarro M, Ruggiero V, Sette C. Targeting TLR\/IL-1R Signalling in Human Diseases. Mediators of Inflammation<\/em>. 2010;2010:1-12. doi:https:\/\/doi.org\/10.1155\/2010\/674363<\/li>\n
  24. O\u2019Neill LAJ. The Interleukin-1 Receptor\/Toll-like Receptor Superfamily: Signal Transduction During Inflammation and Host Defense. Science Signaling<\/em>. 2000;2000(44):re1-re1. doi:https:\/\/doi.org\/10.1126\/stke.442000re1<\/li>\n
  25. Cai Y, Chai Y, Fu Y, et al. Salidroside Ameliorates Alzheimer\u2019s Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis. Frontiers in Aging Neuroscience<\/em>. 2022;13. doi:https:\/\/doi.org\/10.3389\/fnagi.2021.809433<\/li>\n
  26. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature<\/em>. 2012;493(7434):674-678. doi:https:\/\/doi.org\/10.1038\/nature11729<\/li>\n
  27. Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cellular & Molecular Immunology<\/em>. 2021;18(9):2114-2127. doi:https:\/\/doi.org\/10.1038\/s41423-021-00740-6<\/li>\n
  28. Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology<\/em>. 2019;19(8):477-489. doi:https:\/\/doi.org\/10.1038\/s41577-019-0165-0<\/li>\n
  29. Bai H, Zhang Q. Activation of NLRP3 Inflammasome and Onset of Alzheimer\u2019s Disease. Frontiers in Immunology<\/em>. 2021;12. doi:https:\/\/doi.org\/10.3389\/fimmu.2021.701282<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    E. Mazzon1, T. Paolucci2 and O. Trubiani3* 1 Department of Medical, Oral and Biotechnological Sciences, University \u201cG. D’Annunzio\u201d of Chieti-Pescara,...<\/p>\n","protected":false},"author":1033,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[2783],"tags":[1985,154,2595,2790,2789],"class_list":["post-22512","post","type-post","status-publish","format-standard","hentry","category-ejnd-2025-vol-14-issue-n-1","tag-alzheimers-disease","tag-inflammation","tag-neurodegeneration","tag-pattern-recognition-receptor","tag-toll-like-receptor"],"acf":[],"yoast_head":"\nROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases<\/title>\n<meta name=\"description\" content=\"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases\" \/>\n<meta property=\"og:description\" content=\"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"European Journal of Neurodegenerative Diseases\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/piocontieditor\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T11:44:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T12:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"100\" \/>\n\t<meta property=\"og:image:height\" content=\"103\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Biolife Publisher\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ContiPio\" \/>\n<meta name=\"twitter:site\" content=\"@ContiPio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Biolife Publisher\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/\"},\"author\":{\"name\":\"Biolife Publisher\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#\\\/schema\\\/person\\\/b0f9a3a9c8ca5d399f3bc12a8922adcc\"},\"headline\":\"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE\",\"datePublished\":\"2026-01-29T11:44:23+00:00\",\"dateModified\":\"2026-03-11T12:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/\"},\"wordCount\":2260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/adobe-pdf-download-icon-e1713175734457.jpg\",\"keywords\":[\"Alzheimer\u2019s disease\",\"inflammation\",\"neurodegeneration\",\"pattern recognition receptor\",\"Toll-like receptor\"],\"articleSection\":[\"EJND 2025 Vol. 14 issue n. 1\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/\",\"url\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/\",\"name\":\"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/adobe-pdf-download-icon-e1713175734457.jpg\",\"datePublished\":\"2026-01-29T11:44:23+00:00\",\"dateModified\":\"2026-03-11T12:08:45+00:00\",\"description\":\"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/adobe-pdf-download-icon-e1713175734457.jpg\",\"contentUrl\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/adobe-pdf-download-icon-e1713175734457.jpg\",\"width\":100,\"height\":103,\"caption\":\"adobe-pdf-download-icon\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/2026\\\/01\\\/29\\\/role-of-toll-like-receptors-in-alzheimers-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#website\",\"url\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/\",\"name\":\"European Journal of Neurodegenerative Diseases\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#organization\",\"name\":\"Biolife Scientific Publisher\",\"url\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/cropped-image003-1.gif\",\"contentUrl\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/wp-content\\\/uploads\\\/2017\\\/05\\\/cropped-image003-1.gif\",\"width\":512,\"height\":512,\"caption\":\"Biolife Scientific Publisher\"},\"image\":{\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/piocontieditor\",\"https:\\\/\\\/x.com\\\/ContiPio\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.biolife-publisher.it\\\/ejnd\\\/#\\\/schema\\\/person\\\/b0f9a3a9c8ca5d399f3bc12a8922adcc\",\"name\":\"Biolife Publisher\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g\",\"caption\":\"Biolife Publisher\"},\"url\":false}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases","description":"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/","og_locale":"en_GB","og_type":"article","og_title":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases","og_description":"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.","og_url":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/","og_site_name":"European Journal of Neurodegenerative Diseases","article_publisher":"https:\/\/www.facebook.com\/piocontieditor","article_published_time":"2026-01-29T11:44:23+00:00","article_modified_time":"2026-03-11T12:08:45+00:00","og_image":[{"width":100,"height":103,"url":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg","type":"image\/jpeg"}],"author":"Biolife Publisher","twitter_card":"summary_large_image","twitter_creator":"@ContiPio","twitter_site":"@ContiPio","twitter_misc":{"Written by":"Biolife Publisher","Estimated reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#article","isPartOf":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/"},"author":{"name":"Biolife Publisher","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#\/schema\/person\/b0f9a3a9c8ca5d399f3bc12a8922adcc"},"headline":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE","datePublished":"2026-01-29T11:44:23+00:00","dateModified":"2026-03-11T12:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/"},"wordCount":2260,"commentCount":0,"publisher":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#organization"},"image":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg","keywords":["Alzheimer\u2019s disease","inflammation","neurodegeneration","pattern recognition receptor","Toll-like receptor"],"articleSection":["EJND 2025 Vol. 14 issue n. 1"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/","url":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/","name":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE - European Journal of Neurodegenerative Diseases","isPartOf":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg","datePublished":"2026-01-29T11:44:23+00:00","dateModified":"2026-03-11T12:08:45+00:00","description":"Founded in 1987, BIOLIFE is an independent, academic publisher of innovative, high-quality content. We believe in meeting the range of their needs, and in publishing the best of their work.","breadcrumb":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#primaryimage","url":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg","contentUrl":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2024\/04\/adobe-pdf-download-icon-e1713175734457.jpg","width":100,"height":103,"caption":"adobe-pdf-download-icon"},{"@type":"BreadcrumbList","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/2026\/01\/29\/role-of-toll-like-receptors-in-alzheimers-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biolife-publisher.it\/ejnd\/"},{"@type":"ListItem","position":2,"name":"ROLE OF TOLL-LIKE RECEPTORS IN ALZHEIMER\u2019S DISEASE"}]},{"@type":"WebSite","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#website","url":"https:\/\/www.biolife-publisher.it\/ejnd\/","name":"European Journal of Neurodegenerative Diseases","description":"","publisher":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biolife-publisher.it\/ejnd\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#organization","name":"Biolife Scientific Publisher","url":"https:\/\/www.biolife-publisher.it\/ejnd\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#\/schema\/logo\/image\/","url":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2017\/05\/cropped-image003-1.gif","contentUrl":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-content\/uploads\/2017\/05\/cropped-image003-1.gif","width":512,"height":512,"caption":"Biolife Scientific Publisher"},"image":{"@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/piocontieditor","https:\/\/x.com\/ContiPio"]},{"@type":"Person","@id":"https:\/\/www.biolife-publisher.it\/ejnd\/#\/schema\/person\/b0f9a3a9c8ca5d399f3bc12a8922adcc","name":"Biolife Publisher","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e7bce33a125696409d68fb1ff4b921fe53956ddf6605dbf93dc9029ad7471b8c?s=96&d=mm&r=g","caption":"Biolife Publisher"},"url":false}]}},"_links":{"self":[{"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/posts\/22512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/users\/1033"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/comments?post=22512"}],"version-history":[{"count":5,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/posts\/22512\/revisions"}],"predecessor-version":[{"id":22567,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/posts\/22512\/revisions\/22567"}],"wp:attachment":[{"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/media?parent=22512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/categories?post=22512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biolife-publisher.it\/ejnd\/wp-json\/wp\/v2\/tags?post=22512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}